Friday June 23, 2017

Articles:225


5

August 16

Naturally Occurring Antibodies to HIV

Researchers from The Rockefeller University, Howard Hughes Medical Institute, and Aaron Diamond Aids Research Center have found naturally occurring, broadly neutralizing HIV antibodies that mimic the binding site that the virus uses to enter and infect its host cells. These antibodies will be valuable in designing future HIV vaccines. A key feature of the new antibodies is their potency; these new antibodies can neutralize the virus at very low concentrations. This may provide valauable informatin in strengthening a "target" for a future vaccine to HIV.

The paper, “Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding,” was published 14 July 2011 at Science Express.


August 15

Rutgers Researcher Studying Link Between Pollen Release And Climate Change

NEW BRUNSWICK, NJ (WCBS 880) –Sunday’s rain could bring some relief to allergy sufferers.

Ragweed pollen has hit the air a few weeks earlier then usual. It’s a pattern that’s been developing over the past 20 years, says Dr. Leonard Bielory, a Rutgers researcher who is studying the link to climate change.

“We actually note that there’s been a clear trend changing in the release of pollen between that period of time,” said Bielory.

EXTRA: A Guide To Kids’ Colds And Allergies In NYC

He says he won’t discuss the politics or potential causes of climate change, but notes that with more frost-free days, pollen release is starting earlier. That means mild allergy symptoms will likely become moderate and moderate could become more severe.

With an EPA grant, Bielory will study the anticipated pollen release changes over the next 50 years.

http://newyork.cbslocal.com/2011/08/14/rutgers-researcher-studying-link-between-pollen-release-and-climate-change/


August 14

The New Tetanus/ Low Dose Diphtheria Vaccine

The tetanus toxoid/reduced diphtheria toxoid/acellular pertussis single-dose booster vaccine (Tdap;Boostrix, GlaxoSmithKline Biologicals) received approval today from the US Food and Drug Administration (FDA) for adults aged 65 years and older. The vaccine is already licensed for individuals aged 10 to 64 years.

Given as a single-dose booster shot, the vaccine is the first approved to prevent all 3 diseases in seniors. Before today's decision, only vaccines for preventing tetanus and diphtheria were approved in this age group. The vaccone meets a previously unmet need!


August 13

Anti-Tumor Necrosis Factor Treatment and Tuberculosis Infection

Cases of active tuberculosis have been reported worldwide with the use of therapeutic agents that inhibit tumour necrosis factor alpha. TNFα has a central role in the control of mycobacterial infection and disease. Thus, progression of recently acquired tuberculosis infection or reactivation of remotely acquired infection should be expected to occur in patients who require the use of anti-TNF agents. The available in-vitro and epidemiological evidence for the two currently approved agents, infliximab and etanercept, shows that the risk of development of active tuberculosis is greater with infliximab.


August 12

Eosinophilic Esophagitis thought to be Gastroesophageal Reflux Disease

Eosinophilic esophagitis is a chronic inflammation of the esophagus characterized by marked eosinophilic infiltration. It is frequently associated with other allergic diseases. In the last few years, the incidence of eosinophilic infiltration has shown a striking increase in United States, partly due to better knowledge of the disease and to the correct diagnosis of patients previously thought to be suffering from gastroesophageal reflux.


<- | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45->
Location: Springfield, NJ
Today's Date: June 23, 2017
Station Director: Leonard Bielory, M.D
Site Administrator: info@nynjpollen.com